Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2a Evaluation of the Safety and Tolerability of SYN-004 in Adult Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Recipients

Trial Profile

Phase 1b/2a Evaluation of the Safety and Tolerability of SYN-004 in Adult Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Recipients

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ribaxamase (Primary) ; Cefepime; Meropenem; Piperacillin/tazobactam
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Theriva Biologics

Most Recent Events

  • 10 Apr 2025 According to Theriva Biologics media release, data from this study will be featured in an ePoster Flash Session oral presentation at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global), taking place in Vienna, Austria from April 11-15, 2025.
  • 19 Nov 2024 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
  • 19 Nov 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top